We assessed the long-term persistence of humoral immunity against diphtheria in adults with childhood vaccination and the immunogenicity of a booster dose considering demographic, behavioural and vaccinating factors. We conducted a trial in 200 healthy Slovak adults aged 24-65 years, immunised against diphtheria in childhood and against tetanus at regular 10-15 year intervals, and receiving a dose of a tetanus-diphtheria toxoid vaccine. The response was determined by ELISA antibody concentrations of paired sera before and at 4 weeks post-vaccination. A seroprotection rate of 21% (95% confidence interval, CI 15.6-27.3%) was found in adults up to 59 years since the last vaccination with seroprotective levels of antibodies against diphtheria ≥0.1 IU/mL and a geometric mean concentration of 0.05 IU/mL. Conversely, seropositive levels ≥0.01 IU/mL were observed in 98% of adults (95% CI 95-99.5%). Booster-induced seroprotection was achieved in 78% of adults (95% CI 71.6-83.5%) clearly depending on pre-booster antibody levels correlating with age and time since the last vaccination. Moreover, only 54.2% of smokers and 53.3% of patients on statins exhibited seroprotection. Booster vaccination against diphtheria was unable to confer seroprotection in all recipients of only childhood vaccination.

Faculty of Healthcare Alexander Dubček University of Trenčín 911 50 Trenčín Slovakia

Faculty of Pharmacy Comenius University in Bratislava 832 32 Bratislava Slovakia

Faculty of Public Health Slovak Medical University in Bratislava 831 01 Bratislava Slovakia

Jessenius Faculty of Medicine in Martin Comenius University in Bratislava 036 01 Martin Slovakia

Laboratory for Atherosclerosis Research Centre for Experimental Medicine Institute for Clinical and Experimental Medicine 140 21Prague Czech Republic

Preventive Medicine 3rd Faculty of Medicine Charles University Prague 100 00 Prague Czech Republic

Zobrazit více v PubMed

Petráš M., Oleár V. Predictors of the immune response to booster immunisation against tetanus in Czech healthy adults. Epidemiol. Infect. 2018;146:2079–2085. doi: 10.1017/S095026881800242X. PubMed DOI PMC

CDC Vaccine Administration. General Best Practice Guidelines for Immunization, Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP) [(accessed on 15 March 2019)]; Available online: https//www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html#ref24.

WHO Expert Committee on Biological Standardization Sixty-Third Report. WHO Technical Report Series No. 980. [(accessed on 21 June 2019)];2014 Available online: https//www.who.int/biologicals/WHO_TRS_980_WEB.pdf. PubMed

Peduzzi P., Concato J., Kemper E., Holford T.R., Feinstein A.R. A simulation study of the number of events per variable in logistic regression analysis. J. Clin. Epidemiol. 1996;49:1373–1379. doi: 10.1016/S0895-4356(96)00236-3. PubMed DOI

Cohen D., Green M.S., Katzenelson E., Slepon R., Bercovier H., Wiener M. Long-term persistence of anti-diphtheria toxin antibodies among adults in Israel. Implications for vaccine policy. Eur. J. Epidemiol. 1994;10:267–270. doi: 10.1007/BF01719348. PubMed DOI

Edmunds W.J., Pebody R.G., Aggerback H., Baron S., Berbers G., Conyn-van Spaendonck M.A., Hallander H.O., Olander R., Maple P.A., Melker H.E., et al. The sero-epidemiology of diphtheria in Western Europe. ESEN Project. European Sero-Epidemiology Network. Epidemiol. Infect. 2000;125:113–125. doi: 10.1017/S0950268899004161. PubMed DOI PMC

Tanriover M.D., Soyler C., Ascioglu S., Cankurtaran M., Unal S. Low seroprevalence of diphtheria, tetanus and pertussis in ambulatory adult patients, the need for lifelong vaccination. Eur. J. Intern. Med. 2014;25:528–532. doi: 10.1016/j.ejim.2014.04.010. PubMed DOI

Yao N., Zeng Q., Wang Q. Seroepidemiology of diphtheria and pertussis in Chongqing, China, serology-based evidence of Bordetella pertussis infection. Public Health. 2018;156:60–66. doi: 10.1016/j.puhe.2017.12.009. PubMed DOI

Gil A., Dal-Ré R., González A., Lasheras L., Aguilar L., del Rey J. Immunogenicity and safety of a tetanus-diphtheria vaccine (adult type), clinical trial in adults. Med. Clin. (Barc.) 1995;104:126–129. PubMed

Hasselhorn H.M., Nübling M., Tiller F.W., Hofmann F. Factors influencing immunity against diphtheria in adults. Vaccine. 1998;16:70–75. doi: 10.1016/S0264-410X(97)00148-5. PubMed DOI

Lee J., Choi J.H., Wie S.H., Park S.H., Choi S.M., Lee M.S., Kim T.H., Lee H.J., Kang J.H. A phase III study to evaluate the immunogenicity and safety of GC1107 (adult tetanus diphtheria vaccine) in healthy adults. J. Korean Med. Sci. 2019;34:e31. doi: 10.3346/jkms.2019.34.e31. PubMed DOI PMC

Crotty S., Ahmed R. Immunological memory in humans. Semin. Immunol. 2004;16:197–203. doi: 10.1016/j.smim.2004.02.008. PubMed DOI

Hasselhorn H.M., Nübling M., Tiller F.W., Hofmann F. Diphtheria booster immunization for adults. Dtsch. Med. Wochenschr. 1997;122:281–286. doi: 10.1055/s-2008-1047609. PubMed DOI

Choi J.H., Choo E.J., Huh A., Choi S.M., Eom J.S., Lee J.S., Park S.H., Kang J.H. Immunogenicity and safety of diphtheria-tetanus vaccine in adults. J. Korean Med. Sci. 2010;25:1727–1732. doi: 10.3346/jkms.2010.25.12.1727. PubMed DOI PMC

Younas M., Carrat F., Desaint C., Launay O., Corbeau P., ANRS HB03 VIHVAC-B Trial Group Immune activation, smoking, and vaccine response. AIDS. 2017;31:171–173. doi: 10.1097/QAD.0000000000001311. PubMed DOI

Diamantis E., Kyriakos G., Quiles-Sanchez L.V., Farmaki P., Troupis T. The anti-inflammatory effects of statins on coronary artery disease, an updated review of the literature. Curr. Cardiol. Rev. 2017;13:209–216. doi: 10.2174/1573403X13666170426104611. PubMed DOI PMC

Black S., Nicolay U., Del Giudice G., Rappuoli R. Influence of statins on influenza vaccine response in elderly individuals. J. Infect. Dis. 2016;213:1224–1228. doi: 10.1093/infdis/jiv456. PubMed DOI

Omer S.B., Phadke V.K., Bednarczyk R.A., Chamberlain A.T., Brosseau J.L., Orenstein W.A. Impact of statins on influenza vaccine effectiveness against medically attended acute respiratory illness. J. Infect. Dis. 2016;213:1216–1223. doi: 10.1093/infdis/jiv457. PubMed DOI PMC

McLean H.Q., Chow B.D., VanWormer J.J., King J.P., Belongia E.A. Effect of statin use on influenza vaccine effectiveness. J. Infect. Dis. 2016;214:1150–1158. doi: 10.1093/infdis/jiw335. PubMed DOI PMC

Beirne P.V., Hennessy S., Cadogan S.L., Shiely F., Fitzgerald T., MacLeod F. Needle size for vaccination procedures in children and adolescents. Cochrane Database Syst. Rev. 2018;8:CD010720. doi: 10.1002/14651858.CD010720.pub3. PubMed DOI PMC